NASDAQ:CLVS Clovis Oncology (CLVS) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free CLVS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.08▼$1.0952-Week Range N/AVolume1.16 million shsAverage Volume8.88 million shsMarket Capitalization$11.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Clovis Oncology alerts: Email Address Ad Insiders ExposedThis consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About Clovis Oncology Stock (NASDAQ:CLVS)Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.Read More Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here CLVS Stock News HeadlinesMarch 22, 2024 | msn.comClovis’ mayor is a paid member of the Valley Children’s team: what does she do?March 6, 2024 | msn.comClovis West 'Team Eagles' raises money for Leukemia & Lymphoma SocietyMarch 28, 2024 | DTI (Ad)Buy Friday, Sell Monday, No Exceptions Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.December 10, 2023 | msn.comFresno father creates toy drive inspired by son's cancer battle: 'Toys of Hope'December 6, 2023 | msn.comOfficials: Weapon found in backpack at Clovis High SchoolNovember 30, 2023 | msn.comCity of Clovis hosts tree lighting ceremonyOctober 24, 2023 | msn.comFresno hospice nurse diagnosed with stage 4 cancerJuly 19, 2023 | thestreet.comClovis Oncology (CLVS) Stock Gains in After-Hours Trading After 'Breakthrough Therapy' DesignationMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.July 6, 2023 | thestreet.comTesaro Drug Delays Recurrence of Ovarian Cancer, New Clinical Trial ShowsJuly 6, 2023 | thestreet.comWhy Clovis Oncology (CLVS) Stock Hit a One-Year Low TodayMay 21, 2023 | news.yahoo.comWing commander receives key to the city of ClovisMay 17, 2023 | news.yahoo.comNo air conditioning at Clovis East High as Fresno temperatures approach triple digitsMay 11, 2023 | marketwatch.comNon-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Size with Growth Opportunities, Top Countries Data, Future TrendsMay 7, 2023 | usnews.comClovis East High SchoolMarch 22, 2023 | marketwatch.comLuteinizing Hormone Releasing Hormone (LHRH) Agonists Market Growth, Business Development and Analysis Till 2029March 22, 2023 | news.yahoo.comTo improve representation and safety, Fresno and Clovis schools need student councils | OpinionMarch 12, 2023 | bizjournals.comSilicon Valley Bank, a 'strong supporter' of Colorado tech startups, closed by regulatorsJanuary 30, 2023 | reuters.comCLVS.OJanuary 18, 2023 | seekingalpha.comCLVSQ Clovis Oncology, Inc.January 13, 2023 | forbes.comClovis OncologyJanuary 3, 2023 | wsj.comFirm Retention Summary: Clovis Oncology Inc.December 12, 2022 | reuters.comCancer drugmaker Clovis files for bankruptcy, hit by falling salesDecember 12, 2022 | benzinga.comThinking about buying stock in Clovis Oncology, Bank of America, Rivian Automotive, Rent the Runway, or Vipshop Holdings?December 12, 2022 | bizjournals.comBoulder drugmaker Clovis Oncology files for bankruptcyDecember 12, 2022 | finance.yahoo.comClovis Plans to Sell Cancer Drug to Novartis in Bankruptcy DealDecember 12, 2022 | finance.yahoo.comClovis (CLVS) Files for Bankruptcy Amid Lack of Financial AidSee More Headlines Receive CLVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/03/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:CLVS CUSIP18946410 CIK1466301 Webwww.clovisoncology.com Phone303-625-5000Fax303-245-0360EmployeesN/AYear Founded2009Profitability EPS (Most Recent Fiscal Year)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-264,520,000.00 Net Margins-189.37% Pretax Margin-189.68% Return on EquityN/A Return on Assets-57.78% Debt Debt-to-Equity RatioN/A Current Ratio0.14 Quick Ratio0.12 Sales & Book Value Annual Sales$148.76 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($2.15) per share Price / BookN/AMiscellaneous Outstanding Shares144,955,000Free Float138,577,000Market Cap$11.60 million OptionableOptionable Beta0.24 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Patrick J. Mahaffy MA (Age 55)Co-Founder, Chief Exec. Officer, Pres and Exec. Director Dr. Gillian C. Ivers-Read BSc (Age 64)Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations Mr. Daniel W. Muehl CPA (Age 54)Sr. VP of Fin. and Principal Financial & Accounting Officer Dr. Lindsey Rolfe BSc (Age 50)MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance Mr. Corwin Dale Hooks (Age 51)Chief Commercial Officer and Sr. VP Key CompetitorsMolecular TemplatesNASDAQ:MTEMFortress BiotechNASDAQ:FBIOBolt BiotherapeuticsNASDAQ:BOLTAddex TherapeuticsNASDAQ:ADXNGuardion Health SciencesNASDAQ:GHSIView All Competitors CLVS Stock Analysis - Frequently Asked Questions How were Clovis Oncology's earnings last quarter? Clovis Oncology (NASDAQ:CLVS) released its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.08. The biopharmaceutical company had revenue of $37.92 million for the quarter, compared to the consensus estimate of $38.73 million. During the same quarter in the previous year, the firm earned ($0.89) EPS. What is Patrick J. Mahaffy's approval rating as Clovis Oncology's CEO? 12 employees have rated Clovis Oncology Chief Executive Officer Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among the company's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Clovis Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA). This page (NASDAQ:CLVS) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clovis Oncology Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.